Pfizer and Chinese Biotech Company Team Up

NetVation DL Medicine (DL Medicine), a biopharmaceutical company based in China, has scored a two-year collaboration deal with Pfizer, one of the largest companies in the industry. Together, these companies will conduct research into innovative treatments for patients around the world. Furthermore, the deal allows Pfizer to take a financial stake in the Chinese company.
What Will the Companies Research?
Even before this deal with Pfizer, DL Medicine partnered with HitGen to access the company’s DNA-encoded library. The latest partnership will allow all companies involved to leverage this database to discover new interventions for a variety of illnesses.
“We are delighted to announce this collaboration with Pfizer, and we look forward to working together to potentially discover new chemical entities for the treatment of diseases that negatively impact the health of patients worldwide,” said Dr. Wei Chen, the CEO of DL Medicine. As the former leader of drug discovery at HitGen, Chen is intimately familiar with the DNA-encoded library and the program’s potential.
As is the nature of these deals, the exact cures and treatments this partnership may produce is a mystery. However, DL Medicine has made breakthroughs in metabolic, inflammatory, and cancer-related diseases in the past. It’s likely that we’ll continue to see innovation in those areas.
Why Pfizer Invested
As part of this agreement, Pfizer made a serious financial investment in the smaller company, DL Medicine. Yuan-Hua Ding, the Executive Director of External Science and Innovation at Pfizer, believes this research will help the global business heal more patients than ever before.
“New target ideas and novel chemical matter are critical to our success in bringing new therapies to patients around the world,” he said. “This collaboration represents our worldwide commitment to partnering with companies that are doing innovative scientific work to help enhance our portfolio across multiple disease areas.”
Why China?
It’s probably no accident that Pfizer chose a China-based company as its partner in this endeavor. Not only is DL Medicine uniquely qualified to take on this project, but the company is also situated in a booming research and development market. Over the past 20 years, China has become a global leader in scientific discovery. In fact, the country has soared past both the United States and the European Union in this area regarding money spent and outcomes.
The newfound partnership between DL Medicine and Pfizer may bring about some critical medical advancements. Learn more about DL Medicine and Pfizer to follow this significant deal.

Follow us on social media for the latest updates in B2B!

Image

Latest

Brand experience with APL
Stepping into the Future at Shoptalk 2024: Creating a Flagship Brand Experience with APL
March 28, 2024

The customers of today are no longer satisfied with mere products; they crave brands that provide immersive, distinctive, and tailored brand experiences. Athletic Propulsion Labs (APL) epitomizes this shift, setting a new standard in the luxury performance market with its innovative athletic footwear. APL’s newly opened flagship boutique in Soho, with its artisan plaster walls […]

Read More
Balancing professional growth and personal well-being
Routines, Rituals and a Mission-Driven Approach: MarketScale’s CRO Tim Maitland on Balancing Professional Growth and Personal Well-Being
March 28, 2024

In a world that often demands the relentless pursuit of success, finding the sweet spot between professional growth and personal well-being can seem like an elusive goal. As we navigate the complexities of modern work-life dynamics, the conversation around maintaining this balance has become more pertinent than ever. In this episode of Growthwell, we […]

Read More
marketing careers
The Impact of AI on Marketing Careers
March 28, 2024

In this episode of The Marketing AI SparkCast, host Aby Varma, a B2B Marketing Leader and the Founder of Spark Novus, sits down with Matt Gill, the Founder and Managing Partner of MICA Consulting Group. Spark Novus is a consultancy specializing in strategic AI adoption in marketing. MICA is a leading boutique national marketing […]

Read More
healthcare cybersecurity
Continued Threats Require a Major Shift in Healthcare Cybersecurity Risk Perception
March 28, 2024

Recent cyberattacks on healthcare institutions have thrust cybersecurity from a back-office concern to the forefront of the healthcare industry’s agenda. A significant breach at Change Healthcare disrupted essential services, underlining the vulnerability of healthcare networks to such threats and the dire consequences for patient care. Government and industry responses have stressed the importance of […]

Read More